Assignee
XIZANG HAISCO PHARMACEUTICAL CO LTD
CN·3 granted patents·31 pending applications·8 citations·filing 2019–2025
Top patents by PatentIndex Score
34 records- 0192US11964964B2Thyroid hormone receptor agonists and uses thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2019·Granted Apr 23, 2024·8 cites·18 claims
- 0274US12358899B2Thyroid hormone receptor agonists and uses thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2024·Granted Jul 15, 2025·0 cites·13 claims
- 0368US12595270B2Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2025·Granted Apr 7, 2026·0 cites·8 claims
- 0468US2025340555A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0568US2025372228A1Method and system for determining population pharmacokinetic model of propofol and derivative thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0667US2025059186A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0762US2025263426A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0861US2025326765A1Pde4b inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0959US2025171436A1Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use ThereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1059US2025145627A1METTL3 Inhibitor and Composition, and Application of Same in MedicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1159US2025340532A1Heterocyclic compound ccr4 inhibitor and user thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1259US2024383917A1Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1358US2025000988A1Epha2 bicyclic peptide ligand and conjugate thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1458US2025346571A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1558US2025115559A1Preparation method of pyridazinone derivative, and intermediate thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1657US2025195485A1Propionic acid derivative and medical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1757US2025333410A1Compound for inhibiting or degrading bcl6 and use thereof in pharmaceuticsXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1857US2026001868A1Heterocyclic compound capable of inhibiting prmt5-mta and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1956US2024391937A1Bicyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2056US2024208932A1Arylamino derivative estrogen receptor modulator and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2156US2025034168A1Nitrogen-containing heterocyclic derivative parp inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2256US2025382289A1Pyrazolopyridine derivative and application thereof in medicineXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2356US2024092768A1Crystal form of anti-influenza virus compound, preparation method for crystal form, and use of crystal formXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2455US2025222116A1Parp-1 degradation agent and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2555US2024343720A1Aak1 inhibitor and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2655US2025084101A1Compound for inhibiting and degrading irak4, and pharmaceutical composition and pharmaceutical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2754US2024368204A1Small molecular cd73 antagonist and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2853US2025171417A1Heterocyclic derivative, and composition and pharmaceutical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2952US2025179050A1Polymorph as thyroid hormone receptor agonists and use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3052US2024317736A1Deuterated derivative as atx inhibitor, and application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3151US2024408085A1Compound for degradation of bcl-2 family proteins and medical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3250US2024269298A1Phosphonyl derivative, and composition and pharmaceutical application thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3349US2024383874A1Benzene ring derivative, and composition and pharmaceutical use thereofXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3445US2024207353A1Use of peptide amide compound in preparation of drug for treating pruritusXIZANG HAISCO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when XIZANG HAISCO PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →